128 related articles for article (PubMed ID: 22780976)
21. [EBV-positive diffuse large B-cell lymphoma in young individual: report of a case].
Li WS; Xie JL; Zhang M; Zhou XG
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):128-9. PubMed ID: 23710923
[No Abstract] [Full Text] [Related]
22. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma].
Li M; Liu CL; Wang XY; Xue XM; Gao ZF
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229
[TBL] [Abstract][Full Text] [Related]
23. [Diffuse large B-cell lymphoma of testis: a clinicopathologic and immunophenotypic study of 58 cases].
Yang ZR; Bi CF; Zhang WY; Yang QP; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):589-92. PubMed ID: 24314243
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
25. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
26. [Richter syndrome: report of a case].
Chen DB; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):487-8. PubMed ID: 21055184
[No Abstract] [Full Text] [Related]
27. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
Chen DB; Wang Y; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
[No Abstract] [Full Text] [Related]
28. [Peritoneal disseminated recurrence after total gastrectomy for perforated gastric malignant lymphoma--a case report].
Tanizawa Y; Terashima M; Tokunaga M; Bando E; Kawamura T; Kondo J; Waragai M; Motegi Y; Sugisawa N; Ohshima N; Taki Y; Makuuchi R; Miki Y; Yamakawa Y; Kinugasa Y; Kanemoto H; Uesaka K; Onozawa Y
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2155-60. PubMed ID: 21084817
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression of CD-10, BCL-6 and MUM-1 antibodies and immediate clinical response in patients of diffuse large B-cell lymphomas after six cycles of chemotherapy.
Hassan U; Ishtiaq S; Hussain M
J Coll Physicians Surg Pak; 2014 Oct; 24(10):722-7. PubMed ID: 25327914
[TBL] [Abstract][Full Text] [Related]
30. [Submandibular lymphadenopathy].
Wei XJ; Zhou XG; Ren P; Zheng YY; Xie JL; Zheng XD
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):342-4. PubMed ID: 22883676
[No Abstract] [Full Text] [Related]
31. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: report of a case in the oral cavity.
Jaradat JM; Potluri A; Bilodeau EA
Indian J Dent Res; 2013; 24(3):384-6. PubMed ID: 24025890
[TBL] [Abstract][Full Text] [Related]
32. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
[TBL] [Abstract][Full Text] [Related]
34. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
Frick M; Dörken B; Lenz G
Best Pract Res Clin Haematol; 2012 Mar; 25(1):3-12. PubMed ID: 22409819
[TBL] [Abstract][Full Text] [Related]
35. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
36. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
[TBL] [Abstract][Full Text] [Related]
37. [ALK-positive large B-cell lymphoma: report of a case].
Yu H; Huang JX; Wang CF; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):561-2. PubMed ID: 22169650
[No Abstract] [Full Text] [Related]
38. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic analysis of intestinal follicular lymphoma first presenting with gastrointestinal symptoms].
Xie JL; Jin Y; Zheng XD; Wei XJ; Zhu H; Zheng YY; Zhang SH; Zhang YN; Chen GY; Zhou XG
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):320-5. PubMed ID: 22883671
[TBL] [Abstract][Full Text] [Related]
40. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]